Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trail of the German CLL Study Group (GCLLSG).

被引：6
|
作者：
Fischer, Kirsien [1 ]
Stilgenbauer, Stephan [2 ]
Schweighofer, Carmen D. [1 ]
Renschler, Jasmin [1 ]
Busch, Raymonde [3 ]
Kiehl, Michael [4 ]
Balleisen, Leopold [5 ]
Eckart, Michael [6 ]
Fink, Anna M. [1 ]
Boettcher, Sebastian [7 ]
Ritgen, Matthias [7 ]
Kneba, Michael [7 ]
Staib, Peter [1 ]
Doehner, Hartmut [2 ]
Eichhorst, Barbara F. [1 ]
Hallek, Michael [1 ]
机构：
[1] Univ Hosp, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp, Dept Internal Med, Ulm, Germany
[3] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany
[4] Hospital, Dept Internal Med, Frankfurt, Germany
[5] Hospital, Dept Internal Med, Hamm, Germany
[6] ISP Naegelsbacherstr, Erlangen, Germany
[7] Univ Hosp, Dept Internal Med, Kiel, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3106.3106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3106
引用
收藏
页码：913A / 914A
页数：2
相关论文
共 50 条
  • [21] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Wierda, William G.
    Jones, Jeffrey A.
    Swinnen, Lode J.
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [22] NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Kipps, T.
    Swinnen, L.
    Wierda, W.
    Jones, J.
    Coutre, S.
    Smith, M.
    Yang, J.
    Cui, Y.
    Chyla, B.
    Busman, T.
    Enschede, S.
    Humerickhouse, R.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [23] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Swinnen, Lode J.
    Wierda, William G.
    Jones, Jeffrey Alan
    Coutre, Steven E.
    Smith, Mitchell R.
    Yang, Jainning
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2011, 118 (21) : 1669 - 1669
  • [24] Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)
    Von Tresckow, Julia
    Cramer, Paula
    De Silva, Nisha
    Bahlo, Jasmin
    Robrecht, Sandra
    Langerbeins, Petra
    Fink, Anna-Maria
    Al-Sawaf, Othman
    Furstenau, Moritz
    Illmer, Thomas
    Klaproth, Holger
    Tausch, Eugen
    Ritgen, Matthias
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2019, 134
  • [25] Second primary malignancies (SPM) in treated and untreated patients with chronic lymphocytic leukemia (CLL): an analysis of the registry of the German CLL Study Group (GCLLSG)
    Fuerstenau, M.
    Stumpf, T.
    Fink, A. -M.
    Robrecht, S.
    Bahlo, J.
    Maurer, C.
    Linde, H.
    Jacobasch, L.
    Doerfel, S.
    Lipke, J.
    Aldaoud, A.
    Fischer, K.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 19 - 19
  • [26] Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)
    Goergen, Ellinor
    von Tresckow, Julia
    Giza, Adam
    Robrecht, Sandra
    Fink, Anna-Maria
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fuerstenau, Moritz
    Simon, Florian
    Kutsch, Nadine
    Nieper, Pascal
    Tausch, Eugen
    Ritgen, Matthias
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Stilgenbauer, Stephan
    Langerbeins, Petra
    Eichhorst, Barbara
    Hallek, Michael
    Cramer, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S354 - S355
  • [27] Fludarabine, mitoxantrone and cyclophosphamide combination therapy in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: Results of the first interim ananlysis of a phase III study of the German CLL study group (GCLLSG).
    Schmitt, BF
    Franke, A
    Burkhard, O
    Schlag, R
    Hopfinger, G
    Stauch, M
    Bergmann, M
    Wendtner, CM
    Busch, R
    Emmerich, B
    Hallek, N
    BLOOD, 2002, 100 (11) : 364B - 364B
  • [28] Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
    Kutsch, Nadine
    Fink, Anna Maria
    Federhen, Anno
    Giza, Adam
    Robrecht, Sandra
    Stumpf, Janina
    Stoltefuss, Andrea
    Vehling-Kaiser, Ursula
    Koenigsmann, Michael
    Tausch, Eugen
    Schneider, Christof
    Stilgenbauer, Stephan
    Illmer, Thomas
    Schlag, Rudolf
    Doerfel, Steffen
    Gaska, Tobias
    Kiehl, Michael G.
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2022, 140 : 9879 - 9881
  • [29] Sequential treatment with bendamustine, followed by obinutuzumab (GA101) and venetoclax (ABT-199) in patients with chronic lymphocytic leukemia (CLL): results of the CLL2-BAG phase-II-trial of the German CLL study group (GCLLSG)
    Cramer, Paula
    von Tresckow, Julia
    Bahlo, Jasmin
    Robrecht, Sandra
    Al-Sawaf, Othman
    Langerbeins, Petra
    Engelke, Anja
    Fink, Anna-Maria
    Fischer, Kirsten
    Seiler, Till
    von Weikersthal, Ludwig Fischer
    Hebart, Holger
    Kreuzer, Karl-Anton
    Rittgen, Matthias
    Kneba, Michael
    Wendtner, Clemens
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 : 149 - 150
  • [30] Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    Falchi, Lorenzo
    O'Brien, Susan
    Wierda, William
    Faderl, Stefan
    Smith, Susan C.
    Ayala, Ana B.
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2012, 120 (21)
12345